A randomized, open label, single dose, crossover, bioequivalence study of Mebeverin 135mg tablet of Amin Pharm. Co., IRAN in comparison of Duspatalin 135mg tablet of Abbott in 24 healthy adult subjects under fasting condition

Start Date22 Oct 2024

Sponsor / Collaborator

Amin Pharmaceutical Co.

IRCT20190706044111N36 / Suspended

A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Famotidine 40mg tablet of Amin Pharm Co., IRAN in comparison of Famodin® 40mg tablet of Sandoz in 24 healthy adult subjects under fasting condition

Start Date22 Sep 2024

Sponsor / Collaborator

Amin Pharmaceutical Co.

IRCT20130313012810N33 / Completed

Comparative bioequivalence study of the Fexofenadine HCl suspension 30mg/5ml manufactured by Amin Company

Start Date19 Jun 2024

Sponsor / Collaborator

Amin Pharmaceutical Co.

100 Clinical Results associated with Amin Pharmaceutical Co.

0 Patents (Medical) associated with Amin Pharmaceutical Co.

Literatures (Medical) associated with Amin Pharmaceutical Co.

01 Apr 2013·Operative DentistryQ3 · MEDICINE

Effect of Resin-Modified Glass Ionomer Containing Bioactive Glass on the Flexural Strength and Morphology of Demineralized Dentin

Q3 · MEDICINE

Article

Author: Keshani, F ; Khoroushi, M ; Mousavinasab, S-M ; Hashemi, Shirin

SUMMARYIntroduction:Recently, bioactive materials have been incorporated into glass ionomer cements to promote the precipitation of calcium phosphates in surrounding tooth structures. This in vitro study was undertaken to evaluate the effect of resin-modified glass ionomer (RMGI) containing bioactive glass (RMGI-BAG) on the flexural strength (FS) of demineralized dentin.Materials and Methods:A total of 120 dentin bars (2×2×6 mm) were prepared from sound human third molars. Of these, 60 bars were immersed in a demineralizing solution for 96 hours. This produced dentin in two demineralization conditions (DC): untreated and demineralized. Each dentin bar was immersed for 14 days in simulated body fluid (SBF) at 37°C. Three immersion conditions (IC) were investigated: IC1–SBF only; IC2–SBF + an RMGI bar; IC3–SBF + an RMGI-BAG bar. The combination of the DCs and ICs produced six groups (n=20).FS values of the specimens were measured using a three-point bending test. The microstructural changes and the elemental contents of dentin surfaces were evaluated by scanning electron microscopy. Data were analyzed using a two-way analysis of variance (ANOVA) for the effects of the two independent variables, ie, DC and IC, on mean flexural strength. Tukey multiple comparison tests and simple main effects models were used as needed. The significance level of all tests was set at α=0.05.Results:Both DC (p=0.001) and IC (p=0.049) significantly influenced FS (two-way ANOVA). The interaction between DC and IC did not significantly affect FS (p=0.36). For undemineralized dentin, IC did not affect the mean FS (simple main effects model; p=0.4). However, for demineralized dentin, IC significantly affected FS (small main effects model; p=0.008). The Tukey test showed that for demineralized dentin, the mean FS produced by immersion in SBF + RMGI-BAG was significantly stronger than that produced by either immersion in SBF only (p=0.011) or in SBF + RMGI (p=0.034). Scanning electron microscope/energy-dispersive x-ray spectroscopy analyses revealed more calcium and phosphate ions on the surface of dentin immersed in SBF + RMGI-BAG than on dentin immersed in SBF + RMGI.Conclusion:Immersion in SBF + RMGI-BAG increased the FS of demineralized dentin more than immersion in SBF + RMGI.

100 Deals associated with Amin Pharmaceutical Co.

100 Translational Medicine associated with Amin Pharmaceutical Co.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Amin Pharmaceutical Co.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing